Erratum: Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II (Critical Care Medicine (2018) 46 (949–957) DOI: 10.1097/CCM.0000000000003092);Outcomes in patients with vasodilatory shock and renal replacement therapy treated with intravenous angiotensin II

Critical Care Medicine

Volumn 46, Issue 6, 2018, Pages 949-957

  Tumlin, James A ^a   Murugan, Raghavan ^b   Deane, Adam M ^c   Ostermann, Marlies ^d   Busse, Laurence W ^e   Ham, Kealy R ^f   Kashani, Kianoush ^g   Szerlip, Harold M ^h   Prowle, John R ⁱ   Bihorac, Azra ^j   Finkel, Kevin W ^k   Zarbock, Alexander ^l   Forni, Lui G ^m   Lynch, Shannan J ⁿ   Jensen, Jeff ⁿ   Kroll, Stew ⁿ   Chawla, Lakhmir S ⁿ   Tidmarsh, George F ^o   Bellomo, Rinaldo ^c,p,q,r  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g MAYO CLINIC   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

ⁱ ROYAL LONDON HOSPITAL   (United Kingdom)

^j QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^k UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^l UNIVERSITY OF TEXAS   (United States)

^m UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁿ UNIVERSITY OF SURREY   (United Kingdom)

^o La Jolla Pharmaceutical Company   (United States)

^p AUSTIN HOSPITAL   (Australia)

^q ROYAL MELBOURNE HOSPITAL   (Australia)

^r Australian and New Zealand Intensive Care Research Centre   (Australia)

more..

Author keywords

acute kidney injury; acute renal disease; angiotensin II; renal replacement therapy; sepsis; vasodilatory shock

Indexed keywords

ANGIOTENSIN II; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL REPLACEMENT THERAPY; SHOCK; SURVIVAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VASODILATORY SHOCK; COMPLICATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; AGED; ANGIOTENSIN II; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SHOCK; TREATMENT OUTCOME;

EID: 85051098459     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000003226     Document Type: Erratum

References (40)

1. Vincent JL, De Backer D: Circulatory shock. N Engl J Med 2013; 369:1726-1734
2. De Backer D, Biston P, Devriendt J, et al; SOAP II Investigators: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362:779-789
3. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
4. Chawla LS, Bellomo R, Bihorac A, et al; Acute Disease Quality Initiative Workgroup 16: Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 2017; 13:241-257
5. Joannidis M, Druml W, Forni LG, et al: Prevention of acute kidney injury and protection of renal function in the intensive care unit: update 2017: Expert opinion of the Working Group on Prevention, AKI section, European Society of Intensive Care Medicine. Intensive Care Med 2017; 43:730-749
6. Zarjou A, Agarwal A: Sepsis and acute kidney injury. J Am Soc Nephrol 2011; 22:999-1006
7. Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients a multinational, multicenter study. JAMA 2005; 294:813-818
8. Chawla LS, Eggers PW, Star RA, Kimmel PL: Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med 2014; 371:58-66
9. Gaudry S, Hajage D, Schortgen F, et al; AKIKI Study Group: Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375:122-133
10. Zarbock A, Kellum JA, Schmidt C, et al: Effect of early vs delayed initiation of renal replacement therapy on mortality in critically ill patients with acute kidney injury: the ELAIN randomized clinical trial. JAMA 2016; 315:2190-2199
11. Lim HA, Lee HH, Kim AJ, et al: Renin-angiotensin-aldosterone system blockade in critically ill patients is associated with increased risk for acute kidney injury. Tohoku J Exp Med 2016; 238:17-23
12. Langenberg C, Bagshaw SM, May CN, Bellomo R: The histopathology of septic acute kidney injury: a systematic review. Crit Care 2008; 12:R38
13. Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114:5-14
14. Prowle JR, Bellomo R: Sepsis-associated acute kidney injury: macrohemodynamic and microhemodynamic alterations in the renal circulation. Semin Nephrol 2015; 35:64-74
15. Herget-Rosenthal S, Saner F, Chawla LS: Approach to hemodynamic shock and vasopressors. Clin J Am Soc Nephrol 2008; 3:546-553
16. Lankadeva YR, Kosaka J, Evans RG, Bailey SR, Bellomo R, May CN: Intrarenal and urinary oxygenation during norepinephrine resuscitation in ovine septic acute kidney injury. Kidney Int 2016; 90:100-108
17. Abuelo GJ: Normotensive ischemic acute renal failure. N Engl J Med 2007; 357:797-805
18. Wan L, Langenberg C, Bellomo R, May CN: Angiotensin II in experimental hyperdynamic sepsis. Crit Care 2009; 13:R190
19. Khanna A, English SW, Wang XS, et al; ATHOS-3 Investigators: Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 2017; 337:419-430
20. Chawla LS, Russell JA, Bagshaw SM, et al: Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 2017; 19:43-49
21. Kato R, Pinsky MR: Personalizing blood pressure management in septic shock. Ann. Intensive Care 2015; 5:41
22. Busse LW, McCurdy MT, Ali O, Hall A, Chen H, Ostermann M: The effect of angiotensin II on blood pressure in patients with circulatory shock: a structured review of the literature. Crit Care 2017; 21:324
23. Yunge M, Petros A: Angiotensin for septic shock unresponsive to noradrenaline. Arch Dis Child 2000; 82:388-389
24. Wray GM, Coakley JH: Severe septic shock unresponsive to noradrenaline. Lancet 1995; 346:1604.
25. Thomas VL, Nielsen MS: Administration of angiotensin II in refractory septic shock. Crit Care Med 1991; 19:1084-1086
26. Orfanos SE, Armaganidis A, Glynos C, et al: Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 2000; 102:2011-2018
27. Lankadeva YR, Kosaka J, Evans RG, Bellomo R, May CN: Urinary oxygenation as a surrogate measure of medullary oxygenation during angiotensin II therapy in septic acute kidney injury. Crit Care Med 2018; 46:e41-e48
28. Brenner M, Schaer GL, Mallory DL, Suffredini AF, Parrillo JE: Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest 1990; 98:170-179
29. Calzavacca P, Evans RG, Bailey M, Bellomo R, May CN: Variable responses of regional renal oxygenation and perfusion to vasoactive agents in awake sheep. Am J Physiol Regul Integr Comp Physiol 2015; 309:R1226-R1233
30. Bonventre JV, Yang L: Cellular pathophysiology of ischemic acute kidney injury. J Clin Invest 2011; 121:4210-4221
31. May CN, Ishikawa K, Wan L, et al: Renal bioenergetics during early gram-negative mammalian sepsis and angiotensin II infusion. Intensive Care Med 2012; 38:886-893
32. Nakada T, Russell JA, Boyd JH, et al: Association of angiotensin II type 1 receptor-associated protein gene polymorphism with increased mortality in septic shock. Crit Care Med 2011; 39:1641-1648
33. Yang H, Wang Y, Liu L, Hu Q: Increased susceptibility of sepsis associated with CD143 deletion/insertion polymorphism in Caucasians: a meta-analysis. Int J Clin Exp Pathol 2014; 7:6551-6558
34. Zhang W, Chen X, Huang L, et al: Severe sepsis: low expression of the renin-angiotensin system is associated with poor prognosis. Exp Ther Med 2014; 7:1342-1348
35. du Cheyron D, Fradin S, Ramakers M, et al: Angiotensin converting enzyme insertion/deletion genetic polymorphism: its impact on renal function in critically ill patients. Crit Care Med 2008; 36:3178-3183
36. Wunderink RG, Alberton TE, Busse LW: Baseline angiotensin levels and ACE effects in patients with vasodilatory shock treated with angiotensin II. Intensive Care Med Exp 2017; 5:0703
37. Suberviola B, Rodrigo E, Gonzez-Castro A, Serrano M, Heras M, Castellanos-Ortega A: Association between exposure to angiotensinconverting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Intensiva 2017; 41:21-27
38. Corr TD, Takala J, Jakob SM: Angiotensin II in septic shock. Crit Care 2015; 19:98
39. Chen A, Busse LW: Novel therapies for acute kidney injury. Kidney Int Rep 2017; 2:785-799
40. Chawla LS, Busse LW, Brasha-Mitchell E, Alotaibi Z: The use of angiotensin II in distributive shock. Crit Care 2016; 20:137